Price T Rowe Associates Inc Intellia Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

  • $869 Billion
  • Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 582,532 shares of NTLA stock, worth $9.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
582,532
Previous 1,244,959 53.21%
Holding current value
$9.16 Million
Previous $27.9 Million 57.03%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$19.72 - $27.36 $13.1 Million - $18.1 Million
-662,427 Reduced 53.21%
582,532 $12 Million
Q2 2024

Aug 14, 2024
SELL
$20.02 - $27.22 $7.61 Million - $10.3 Million
-380,092 Reduced 23.39%
1,244,959 $27.9 Million
Q1 2024

May 15, 2024
SELL
$23.82 - $32.8 $4.98 Million - $6.86 Million
-209,092 Reduced 11.4%
1,625,051 $44.7 Million
Q4 2023

Feb 14, 2024
SELL
$23.16 - $32.34 $4.98 Million - $6.96 Million
-215,077 Reduced 10.5%
1,834,143 $55.9 Million
Q3 2023

Nov 14, 2023
SELL
$31.62 - $45.78 $356,389 - $515,986
-11,271 Reduced 0.55%
2,049,220 $64.8 Million
Q2 2023

Aug 14, 2023
BUY
$34.58 - $46.03 $6.6 Million - $8.78 Million
190,730 Added 10.2%
2,060,491 $84 Million
Q1 2023

May 15, 2023
SELL
$33.3 - $44.82 $1.98 Million - $2.67 Million
-59,594 Reduced 3.09%
1,869,761 $69.7 Million
Q4 2022

Feb 14, 2023
BUY
$33.21 - $62.69 $6.38 Million - $12 Million
192,095 Added 11.06%
1,929,355 $67.3 Million
Q3 2022

Nov 14, 2022
SELL
$53.92 - $71.7 $16.7 Million - $22.2 Million
-310,071 Reduced 15.15%
1,737,260 $97.2 Million
Q2 2022

Aug 15, 2022
SELL
$38.49 - $76.21 $6.64 Million - $13.1 Million
-172,540 Reduced 7.77%
2,047,331 $106 Million
Q1 2022

May 16, 2022
BUY
$58.27 - $118.99 $6.96 Million - $14.2 Million
119,523 Added 5.69%
2,219,871 $161 Million
Q4 2021

Feb 14, 2022
SELL
$100.76 - $138.36 $24.6 Million - $33.8 Million
-244,190 Reduced 10.42%
2,100,348 $248 Million
Q3 2021

Nov 15, 2021
SELL
$132.37 - $176.78 $18.8 Million - $25.1 Million
-141,953 Reduced 5.71%
2,344,538 $315 Million
Q2 2021

Aug 16, 2021
BUY
$60.88 - $161.91 $9.86 Million - $26.2 Million
162,001 Added 6.97%
2,486,491 $403 Million
Q1 2021

May 17, 2021
BUY
$46.59 - $83.68 $9.49 Million - $17 Million
203,607 Added 9.6%
2,324,490 $187 Million
Q4 2020

Feb 16, 2021
BUY
$18.83 - $63.53 $39.9 Million - $135 Million
2,120,883 New
2,120,883 $115 Million

Others Institutions Holding NTLA

# of Institutions
314
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.2B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email